These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32882146)

  • 1. New drugs under development for COPD.
    Lo Bello F; Hansbro PM; Donovan C; Coppolino I; Mumby S; Adcock IM; Caramori G
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):419-431. PubMed ID: 32882146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of new drugs for COPD.
    Barnes PJ
    Curr Med Chem; 2013; 20(12):1531-40. PubMed ID: 22963554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.
    Monaco TJ; Hanania NA
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):285-299. PubMed ID: 28868931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
    Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
    Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs under development for COPD.
    Uwagboe I; Adcock IM; Lo Bello F; Caramori G; Mumby S
    Minerva Med; 2022 Jun; 113(3):471-496. PubMed ID: 35142480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontrunners in novel pharmacotherapy of COPD.
    Barnes PJ
    Curr Opin Pharmacol; 2008 Jun; 8(3):300-7. PubMed ID: 18457992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging pharmaceutical therapies for COPD.
    Lakshmi SP; Reddy AT; Reddy RC
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2141-2156. PubMed ID: 28790817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
    Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D
    Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.
    Miravitlles M; D'Urzo A; Singh D; Koblizek V
    Respir Res; 2016 Sep; 17(1):112. PubMed ID: 27613392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease.
    Compton C; McBryan D; Bucchioni E; Patalano F
    Pulm Pharmacol Ther; 2013 Oct; 26(5):562-73. PubMed ID: 23748050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future directions in the pharmacologic therapy of chronic obstructive pulmonary disease.
    Buhl R; Farmer SG
    Proc Am Thorac Soc; 2005; 2(1):83-93. PubMed ID: 16113474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can β2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?
    Zhang WH; Zhang Y; Cui YY; Rong WF; Cambier C; Devillier P; Bureau F; Advenier C; Gustin P
    Fundam Clin Pharmacol; 2012 Feb; 26(1):118-34. PubMed ID: 22044554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
    Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
    Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
    Mastrodicasa MA; Droege CA; Mulhall AM; Ernst NE; Panos RJ; Zafar MA
    Expert Opin Investig Drugs; 2017 Feb; 26(2):161-174. PubMed ID: 28004591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging pharmacotherapies for COPD.
    Barnes PJ
    Chest; 2008 Dec; 134(6):1278-1286. PubMed ID: 19059958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future Advances in COPD Therapy.
    Barnes PJ
    Respiration; 2001; 68(5):441-8. PubMed ID: 11694802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs).
    Ti H; Zhou Y; Liang X; Li R; Ding K; Zhao X
    J Med Chem; 2019 Jul; 62(13):5944-5978. PubMed ID: 30682248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.